

Women's Health Drug Therapy

May 7, 2008

DISCLOSURE INFORMATION

It is the policy of the University of Washington School of Nursing to ensure balance, independence, objectivity, and scientific rigor in all of its educational offerings. Speakers and planning committee members are required to disclose any financial or other relationships with a proprietary entity producing health care goods or services. Conflict of interest develops when an individual has an opportunity to affect educational content about the products or services of a commercial interest with which the individual has a financial relationship. The intent of this policy is to openly identify any such relationships so that a) UW Continuing Nursing Education can identify conflicts of interest which may have been created and b) learners can form their own opinions as to whether content reflects possible bias in exposition or conclusion. Speakers are also required to disclose to participants when discussing off-label use of a product for a purpose other than that for which it was approved by the Food and Drug Administration.

I. RELATIONSHIP INFORMATION

A. The following individuals attest that they have no relationships to disclose.

Speaker

Jacqueline Siegel, MN, ARNP, CDE, BC-ADM
Barbara Parkman, MN, ARNP

Speaker

Margaret Cashman, MD, ACP
Frances E. Broyles, MD

Planning Committee Member

Vicki L. Fox, MSN, ARNP
Sheila Keener, BSN, RN
Martine Lewis, MS, ARNP
Pamela Van Pelt, MSN, CNM

Planning Committee Member

Suzanne Lindberg, MN, ARNP
Martha DuHamel, MPH
Mary Ellen Maxell, MN, ARNP
Linda Johnson Trippett, MSN, RN

B. The following individuals disclosed the described relationships.

Speaker

Carolyn Livingston, PhD, ARNP
Robin Kroll, MD, FACOG

Description of Relationship

Salary, Honoraria-Wyeth Pharmaceutical Company
Salary, Honoraria-Wyeth Pharmaceutical Company,
Roche, Barr
Consulting, Speaking & Teaching-Novartis,
Berlex and Roche

Planning Committee Member

Michael V. Vitiello, PhD

Description of Relationship

Consulting, Speaking & Teaching-Takeda Pharmaceutical

II. PRODUCT DISCLOSURE INFORMATION

The following individuals indicated that their presentations may include discussion of unapproved, investigational, or off-labeled uses of commercial products.

Speaker

Robin Kroll, MD, FACOG

Product Use

Estrogens-Approved, Investigational and Not approved
Progestin-Approved, Investigational and Not approved
Clonidine-Approved, Investigational and Not approved
Prazocin-Not approved
Guanfacine-Investigational and Not approved
Antidepressants and Antihistamines-Not approved
Melatonin-Not approved

Margaret Cashman, MD, ACP

Barbara Parkman, MN, ARNP